Anti-Glycosidase (Glycoside Hydrolase) Antibody Development Service
Glycosidases, also known as glycoside hydrolases, are a vast family of enzymes responsible for breaking down complex carbohydrates. Their activity is critical for basic lysosomal function, pathogen invasion, and tumor remodeling. At Creative Biolabs, we provide specialized anti-glycosidase antibody development services designed to support both fundamental research and therapeutic innovation. Whether you are investigating lysosomal storage disorders, targeting metastatic enzymes like heparanase, or developing antibodies for sophisticated Antibody-Directed Enzyme Prodrug Therapy (ADEPT) research systems, our platform delivers high-specificity binders tailored to your needs. This service is part of our broader Anti-Glycan Related Enzyme Antibody Development Service, offering researchers a comprehensive toolkit for exploring the glyco-enzymatic landscape.
Background: Glycosidases in Disease and Therapy Research
Glycosidases catalyze the hydrolysis of glycosidic bonds in complex sugars. While essential for healthy cellular metabolism, dysregulated glycosidase activity is a hallmark of many pathologies. For instance, the overexpression of heparanase—an endo-beta-glucuronidase—is directly linked to tumor angiogenesis and metastasis, making it a prime target for therapeutic antibodies. Similarly, viral neuraminidase (sialidase) is critical for the release of influenza virions, and specific anti-neuraminidase antibodies are sought after for their broad neutralizing potential in preclinical studies.
Functional Classification of Targetable Glycosidases
| Category | Mechanism | Key Examples & Research Targets |
|---|---|---|
| Exo-glycosidases | Cleave terminal sugar residues from the non-reducing end of glycans. | Neuraminidase (Sialidase), Beta-Galactosidase, Mannosidase, Glucosidase |
| Endo-glycosidases | Cleave internal glycosidic bonds within the carbohydrate chain. | Heparanase, Chitinase, Endo-beta-N-acetylglucosaminidase |
| Lysosomal Glycosidases | Function in acidic lysosomes to degrade glycoconjugates; deficiency leads to storage diseases. | Alpha-Galactosidase A, Beta-Glucosidase (GBA), Alpha-Mannosidase |
Mechanistic Implications in Pathology
The role of glycosidases extends beyond simple degradation. They are active participants in disease progression and therapeutic strategies.
- Tumor Microenvironment Remodeling: Enzymes like heparanase degrade the extracellular matrix (ECM), releasing sequestered growth factors and clearing a path for tumor cell invasion.
- Viral Propagation: Influenza neuraminidase cleaves sialic acids on the host cell surface, preventing viral aggregation and facilitating the release of progeny virions.
- Prodrug Activation (ADEPT): In this therapeutic strategy, a non-human glycosidase (e.g., bacterial beta-glucosidase) is targeted to the tumor. It then converts a non-toxic prodrug into a potent cytotoxic agent locally, sparing healthy tissue.
Streamlined Workflow for Anti-Enzyme Antibody Discovery
Request a Quote for Your Enzyme Target
Comprehensive Anti-Glycosidase Antibody Services
Our platform covers the entire spectrum of carbohydrate-active enzymes (CAZymes), with a strong focus on glycosidases relevant to cancer therapy and metabolic disease.
Anti-Heparanase Antibody Development
Heparanase cleaves heparan sulfate side chains on proteoglycans, remodeling the extracellular matrix (ECM) to facilitate tumor invasion. We develop heparanase neutralizing antibodies that block this enzymatic activity, facilitating research into potential therapeutic routes to inhibit metastasis. We also provide non-neutralizing antibodies for immunohistochemical (IHC) detection of heparanase in tumor biopsies.
Anti-Sialidase Antibody Development
Neuraminidases (sialidases) remove sialic acid residues from glycoconjugates. In virology, we generate broad-spectrum influenza neuraminidase antibodies and viral neuraminidase antibodies that can be used to study the inhibition of viral egress. In oncology, we target mammalian sialidases like NEU1, NEU2, NEU3, and NEU4, which are implicated in cell signaling and cancer progression.
Anti-Mannosidase Antibody Development
Targeting both acidic lysosomal alpha-mannosidases involved in catabolism and Golgi mannosidases crucial for N-glycan maturation. These antibodies are vital for studying glycoprotein quality control and congenital disorders of glycosylation.
Anti-Hyaluronidase Antibody Development
Hyaluronidases degrade hyaluronan in the extracellular matrix, influencing tissue integrity and tumor progression. We develop antibodies to monitor Hyal-1, Hyal-2, and PH-20 expression, facilitating research into stromal remodeling and therapeutic drug dispersion.
Targeting the Alpha-1/2 Linkage Machinery
Many disease-associated glycans depend on specific linkages. We develop antibodies against enzymes that cleave these bonds, such as alpha-1 fucosidases or alpha-2 sialidases. Targeting these enzymes allows researchers to manipulate the density of specific glycan epitopes on the cell surface, providing a method to intervene in cell adhesion and immune evasion processes.
Service Highlights and Advantages
Enzyme Function Assays
We integrate enzymatic activity assays into the screening phase to distinguish between neutralizing and non-neutralizing clones.
Broad CAZyme Coverage
From mannosidase antibodies to chitinase antibodies, we cover diverse glycoside hydrolase families.
ADEPT Optimization
Tailored screening for antibodies that stabilize enzymes or detect them in complex sera for PK analysis.
Cross-Species Reactivity
We validate binding against human, mouse, and viral (e.g., influenza NA) homologs to ensure appropriate model usage.
Start Your Project
Accelerate your glycosidase research with high-quality antibody tools. Whether you are developing an anti-glycosidase antibody for therapeutic inhibition studies or for the bioanalysis of an ADEPT construct, Creative Biolabs has the expertise to deliver. Contact our team to discuss your target enzyme and assay requirements.
Contact Us for a Quote
Published Data
Targeting heparanase, the endoglycosidase responsible for cleaving heparan sulfate side chains, offers a strategic avenue to disrupt the pro-tumorigenic remodeling of the extracellular matrix. Recent preclinical investigations have validated a novel IgG1 monoclonal antibody that exhibits potent neutralizing capabilities against this critical enzyme. Structural studies reveal that the antibody binds specifically to the heparin-binding domain II (HBD-II), effectively occluding the active site cleft and preventing substrate access through steric hindrance. This binding mechanism not only inhibits direct enzymatic degradation of the matrix but also significantly attenuates the cellular uptake and subsequent activation of the latent pro-enzyme.
The therapeutic impact of this antibody was rigorously evaluated in immunocompetent murine models of pancreatic ductal adenocarcinoma. As illustrated in the accompanying data, the antibody demonstrated substantial efficacy as a monotherapy, significantly retarding tumor expansion. Most notably, when administered in combination with standard chemotherapeutic agents like gemcitabine, the treatment yielded a profound synergistic inhibition of tumor progression. The combination regimen resulted in a marked reduction in both tumor volume and final tumor mass compared to monotherapy or vehicle controls. These results powerfully underscore the potential of anti-glycosidase antibodies to sensitize aggressive tumors to chemotherapy by altering the tumor microenvironment.
Fig.1 Synergistic inhibition of pancreatic tumor growth by anti-heparanase antibody and chemotherapy. (A) Tumor volume kinetics; (B) Final tumor weights demonstrating enhanced efficacy.1
FAQs
Do you offer antibodies that inhibit enzyme activity (neutralizing antibodies)?
Yes. We can design screening assays to specifically identify clones that bind to the catalytic site of the glycosidase (e.g., heparanase or sialidase), thereby inhibiting its function. This is ideal for therapeutic discovery and development research.
Can you generate antibodies against bacterial enzymes used in ADEPT?
Absolutely. We have extensive experience raising antibodies against non-human enzymes, such as bacterial beta-galactosidase or glucarpidase (carboxypeptidase G2), which are frequently used in ADEPT to activate prodrugs. We can validate these antibodies for PK assays to measure enzyme clearance in serum.
What is the difference between Anti-Glycosidase and Anti-Glycosyltransferase antibodies?
Anti-Glycosidase antibodies target enzymes that break down glycans (hydrolases), such as neuraminidase or heparanase. Anti-Glycosyltransferase antibodies target enzymes that build glycans (transferases), such as FUT8 or ST6GAL1. We develop antibodies for both categories of CAZymes.
Can you distinguish between NEU1, NEU2, NEU3, and NEU4?
Yes. The human neuraminidase (sialidase) family shares structural homology, but we can design peptide immunogens corresponding to unique variable regions of each isoform. We then perform cross-reactivity screening to ensure the final antibody is specific to your target isoform (e.g., NEU3 antibody).
Do you support development for viral targets like Influenza Neuraminidase?
Yes. We develop viral neuraminidase antibodies (anti-NA) for influenza research. We can screen for broadly neutralizing antibodies that recognize conserved epitopes across different viral strains or subtypes.
What Our Customers Say
"We needed a specific antibody for our ADEPT system to detect the beta-glucosidase payload in mouse serum. Creative Biolabs delivered a high-affinity clone that didn't interfere with the enzyme's activity. Perfect for our PK studies."
"The anti-heparanase antibodies we ordered showed excellent inhibition in our invasion assays. The team was very helpful in selecting the right immunogen strategy to target the active site."
"Identifying specific markers for lysosomal storage diseases is tough. Their custom development service for NEU1 antibodies provided us with reagents that worked beautifully in both Western blot and IHC."
"We are studying viral entry and needed antibodies against influenza neuraminidase. The library screening was fast, and the data package was comprehensive. Highly recommended."
Reference:
- Barash, U. et al. "Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis." Cells 14 (2025): 1379. Distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). https://doi.org/10.3390/cells14171379
Supports
- Glycosylation Analysis
- Glycosyltransferase & Glycosidase Substrate Microarray
- Custom Glycosylation of Biomolecules